Study at a glance
Why is the wrong vitamin D blood test sometimes ordered?
This page examines why clinicians sometimes choose the wrong vitamin D blood test. The usual test measures 25-hydroxyvitamin D to assess vitamin D levels. A different test measures 1,25-dihydroxyvitamin D, the active hormone, for particular medical questions. Calling a form active does not make it the better test for every purpose.
How did researchers study the choice of vitamin D blood tests?
Two studies examined test ordering in hospitals after computer systems changed. Research reviews also examined how vitamin D forms differ and how laboratory methods affect results. These were studies of testing and interpretation, not trials showing that more testing improves health.
Did clearer hospital ordering systems reduce use of the wrong vitamin D test?
One medical centre found 43 sets of electronic ordering options that included the active-hormone test instead of the usual test. Staff had intended those options for routine vitamin D checks. Correcting the options, adding a warning and educating clinicians reduced active-hormone test orders. In a separate study at two hospitals, clearer test names also reduced orders for that test.
Why does the vitamin D blood test need to match the medical question?
The test needs to match the question. A normal active-hormone result does not rule out low 25-hydroxyvitamin D. Even the usual test can be affected by laboratory methods and changes in the body. These findings do not show that everyone needs testing or that either blood result directly measures vitamin D’s effects in tissues.
Read the full article below ↓Vitamin D testing can fail before a sample ever reaches the analyser: the wrong metabolite can be ordered for the clinical question. The most important example is using 1,25-dihydroxyvitamin D as though it were a routine measure of vitamin D status. Evidence from laboratory medicine, real-world ordering systems and assay studies shows why this mistake occurs, why it can mislead, and why choosing 25-hydroxyvitamin D does not eliminate the need for careful interpretation.
The first question is not “what is the vitamin D level?” but “what are we trying to measure?”
A request for “vitamin D” is ambiguous because the pathway contains multiple measurable metabolites. For ordinary assessment of circulating vitamin D status, total 25(OH)D is the established biomarker. Circulating 1,25(OH)₂D answers a different question: it reflects the tightly regulated active endocrine hormone and is mainly useful in selected disorders of activation, resistance, calcium or phosphate regulation. Confusing these roles can produce a technically accurate laboratory number that is physiologically inappropriate for the question being asked.
That boundary is central to Limitations of Vitamin D Blood Tests. A blood test is only informative when the measurand, analytical method and physiological interpretation all match the purpose of testing.
Real-world evidence shows that the two tests are genuinely confused
Krasowski and colleagues documented a striking example after implementation of a new electronic medical record at an academic medical centre. Ordering of 1,25(OH)₂D rose substantially. Investigation found 43 electronic order sets that contained 1,25(OH)₂D but not 25(OH)D. Ten had the active-hormone test preselected, and in three it could not be deselected when the order set was used.
When the clinical owners of those order sets were contacted, the intended purpose in every case was routine vitamin D status screening. The problem was therefore not a rare disagreement over interpretation: the wrong test had been built into the ordering environment. After the order sets were corrected, a warning prompt was added and clinicians were educated, 1,25(OH)₂D ordering fell back toward earlier levels.
A second hospital study independently reproduced the same human-factors problem
White and colleagues later examined vitamin D ordering at two affiliated academic hospitals. Following computerised provider order entry, monthly 1,25(OH)₂D testing increased by an estimated 24.8 tests at one hospital and 14.2 at the other. The investigators changed the test names so that their clinical purpose and relative rarity were clearer. Monthly 1,25(OH)₂D orders then fell by an estimated 22.1 and 11.3 tests respectively, with all four changes reported as statistically significant.
The importance of this study is not that interface design determines physiology. It is that similarly named metabolites create a predictable selection error. Clinicians can confuse “active” with “best measure of status,” or choose both tests when they are uncertain. Clearer naming reduced the inappropriate ordering signal in two separate hospitals without requiring a blanket prohibition on the specialist test.
Why 1,25(OH)₂D can mislead when the question is nutritional status
The active hormone is produced under strong endocrine control. PTH, FGF23, renal CYP27B1 and feedback can maintain or alter circulating 1,25(OH)₂D independently of the size of the 25(OH)D substrate pool. This means a normal active-hormone concentration can coexist with low 25(OH)D. In very severe deficiency the active hormone can eventually fall, but that does not make it a more direct measure of stores; it reflects failure of the compensatory system as substrate becomes inadequate.
The wrong-marker risk therefore runs in both directions. A normal 1,25(OH)₂D result can falsely reassure someone whose 25(OH)D is low, while a low 1,25(OH)₂D result can be driven by renal or endocrine abnormalities that are not equivalent to nutritional vitamin D deficiency. The physiological comparison is developed in Vitamin D Testing: 25-OH-D vs 1,25-OH₂-D.
1,25(OH)₂D still has legitimate specialist indications
Avoiding inappropriate use must not become a rule that 1,25(OH)₂D should never be measured. Clinical laboratory reviews identify circumstances in which it adds information precisely because it is the active hormone. These include selected disorders of 1α-hydroxylase activity, hereditary vitamin D resistance, granulomatous or lymphoproliferative conditions with hypercalcaemia, and some hypophosphataemic disorders in which the pattern of active hormone helps distinguish regulatory mechanisms.
The correct principle is question matching. 25(OH)D is the usual status marker. 1,25(OH)₂D is a specialised physiological or diagnostic marker when the clinical problem concerns activation, inappropriate production, resistance or mineral-regulatory pathways.
Choosing 25(OH)D does not make interpretation automatic
There is a second layer of risk: selecting the correct metabolite but treating the result as analytically or biologically perfect. Dirks, Cavalier and Heijboer reviewed the principal 25(OH)D measurement approaches and emphasised that automated assays do not perform equally well in every patient group. Vitamin D₂ supplementation can be a particular challenge for some methods, and matrix or binding-related differences can create method-dependent bias. Appropriately developed and standardised LC-MS/MS methods can be preferable in settings where automated assays are unreliable.
Earlier reviews describe the same general problem from a different era of assay development: vitamin D metabolites are hydrophobic, occur in multiple forms and can be affected by extraction, binding and matrix effects. The technical landscape has improved, but the interpretive lesson remains current. A result is not just a molecule name and a number; it is the output of a particular analytical method applied to a particular specimen in a particular physiological context.
1,25(OH)₂D measurement is analytically demanding for a different reason
Circulating 1,25(OH)₂D occurs at concentrations roughly orders of magnitude below 25(OH)D, making measurement more technically demanding. Specialized methods have improved sensitivity, but low abundance, cross-reactivity and inter-assay differences remain important considerations. These analytical difficulties reinforce the need to order the active hormone for a defined clinical purpose rather than as a reflex “more active must be more informative” test.
Biological variation can be mistaken for meaningful change
Even a correctly chosen and accurately measured biomarker is sampled from a living system. Exposure, season, illness, timing and short-term physiological variation can move a blood value without representing an equivalent change in long-term vitamin D physiology. Biological Noise in Vitamin D Testing addresses this separate source of uncertainty. The important point is that biomarker choice, analytical performance and biological variability are independent layers: getting one right does not automatically solve the other two.
A correct biomarker is not the same as a universal reason to test
Current preventive guidance adds an important boundary. The 2024 Endocrine Society guideline suggests against routine 25(OH)D screening in generally healthy adults who do not otherwise have an established indication for testing. It also notes that outcome-specific 25(OH)D thresholds have not been established in clinical trials for these generally healthy populations.
This does not overturn the laboratory principle that 25(OH)D is the appropriate status biomarker. It separates two decisions that are often collapsed: first, if vitamin D status genuinely needs to be measured, which metabolite answers that question; second, does the person or population actually have a clinical reason to measure it? The evidence supports 25(OH)D for the first question, while the second depends on clinical context and should not be assumed from the existence of the test.
The two ordering studies reveal more than a software problem
The Iowa and Washington studies used different institutions and different interventions, yet they exposed the same underlying vulnerability. In one, erroneous order sets placed 1,25(OH)₂D directly into routine workflows. In the other, the presentation and naming of the tests in the electronic catalogue encouraged selection of the rarer active-hormone assay. Both studies then showed that correcting the decision environment reduced inappropriate 1,25(OH)₂D use.
This replication matters because it makes the error less easy to dismiss as an isolated local mistake. The names are intrinsically easy to confuse, and the word “active” can sound more clinically informative than “25-hydroxy.” The evidence shows that test-selection systems need to communicate purpose, not merely metabolite chemistry. A technically precise name can still be a poor clinical interface if it does not help the user distinguish status testing from active-hormone investigation.
Analytical quality and physiological appropriateness are separate tests
A laboratory can measure the wrong metabolite with excellent analytical precision. It can also measure the correct metabolite with a method that has clinically important bias in a particular patient group. These are different failure modes. The first is a question-selection error; the second is a measurement-performance error. Good interpretation requires both to be addressed independently.
This distinction is particularly important for 25(OH)D because its status-marker role is sometimes treated as though it guarantees universal comparability. Modern automated assays are convenient and often adequate, but Dirks and colleagues describe settings in which LC-MS/MS provides more reliable measurement, including circumstances involving vitamin D₂. Standardisation programmes have improved comparability, yet method awareness remains part of responsible interpretation when results are unexpected or clinically discordant.
A result can be physiologically correct and still be clinically misread
Misinterpretation does not require a laboratory error. A normal 1,25(OH)₂D result may be perfectly accurate while being falsely used to dismiss low 25(OH)D status. A low 25(OH)D result may be accurately measured while being treated as a direct measure of tissue response. A result near a decision boundary may be analytically sound while biological variation makes a small change between two samples less meaningful than it appears.
The evidence therefore supports restraint at the final interpretive step. Biomarkers describe defined biological quantities. They do not automatically supply the diagnosis, causal explanation, treatment threshold or tissue-level effect that a reader may be tempted to attach to the number.
For the same reason, reflexively ordering both metabolites is not a neutral solution to uncertainty. It can add a second number whose physiology is easy to misread, increase cost, and create apparent discordance that requires further interpretation. Additional testing earns value only when the second metabolite answers an additional defined question. The ordering studies are important because they show that indiscriminate addition can arise from interface design rather than from a genuine diagnostic need.
Common interpretation errors
- Ordering 1,25(OH)₂D for routine status assessment because it is the “active” form.
- Treating a normal 1,25(OH)₂D concentration as proof that vitamin D status is adequate.
- Treating a low 1,25(OH)₂D concentration as synonymous with nutritional vitamin D deficiency without considering kidney and mineral-endocrine physiology.
- Assuming every 25(OH)D assay is interchangeable in every patient and treatment context.
- Treating a single 25(OH)D result as a direct measure of tissue-level vitamin D effect.
- Equating the availability of a correct status biomarker with a recommendation for routine testing of everyone.
A disciplined way to interpret vitamin D biomarkers
Interpretation is strongest when it proceeds in order. Define the physiological or clinical question first. Match that question to the metabolite. Consider whether renal, calcium, phosphate, PTH or FGF23 physiology could change the expected relationship between 25(OH)D and 1,25(OH)₂D. Then consider the assay method and the possibility of biological variation before turning the number into a conclusion.
This approach also keeps Vitamin D Status vs Vitamin D Effect separate from laboratory status. A 25(OH)D result can be useful without being a complete model of tissue response, and a specialised 1,25(OH)₂D result can be useful without being a better nutritional-status test.
What the evidence supports
The strongest evidence supports a simple but carefully bounded rule: use the biomarker that answers the question. When the question is ordinary vitamin D status, 25(OH)D is the appropriate circulating marker. When the question concerns active-hormone regulation or selected disorders of calcium, phosphate, activation or resistance, 1,25(OH)₂D may add clinically relevant information. Neither test should be interpreted as a context-free verdict.
For a faster version of this evidence, see Choosing the Correct Vitamin D Biomarker: Clinical Limitations and Misinterpretation Risks: Study Summary.
Primary evidence and source details
Promoting improved utilization of laboratory testing through changes in an electronic medical record: experience at an academic medical center. Krasowski MD et al. BMC Medical Informatics and Decision Making. 2015;15:11. PMID 25880934.
Optimizing vitamin D naming conventions in computerized order entry to support high-value care. White AA, McKinney CM, Hoffman NG, Sutton PR. Journal of the American Medical Informatics Association. 2017;24:172 to 175. PMID 27107453.
The When, What & How of Measuring Vitamin D Metabolism in Clinical Medicine. Dirks NF et al. Nutrients. 2018;10:482. PMID 29652819.
Vitamin D: marker, measurand & measurement. Dirks NF, Cavalier E, Heijboer AC. Endocrine Connections. 2023;12:e220269. PMID 36688810.
Assessment and Interpretation of Circulating 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D in the Clinical Environment. Hollis BW. Endocrinology and Metabolism Clinics of North America. 2010;39:271 to 286. PMID 20511051.
Vitamin D for the Prevention of Disease. Endocrine Society clinical practice guideline. Last updated 3 June 2024.
Related reading
Why Normal 1,25-Dihydroxyvitamin D Does Not Rule Out Low Vitamin D Status
Learn why normal 1,25-dihydroxyvitamin D does not rule out low vitamin D status and how hormonal regulation can preserve active vitamin D levels.
Read more →Longitudinal biomarker trajectories accompanying trichoscopic change after PRP-based regimens for alopecia: a complementary multi-marker analysis of a real-world cohort
This study aimed to provide a complementary longitudinal analysis of the same real-world treatment cohort, focusing on within-subject trichoscopic change and paired biomarker trajectories rather than on baseline response stratification.
Original paper ↗Read more →25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D: Physiological Meaning and Regulation: Full Study
Explore why 25(OH)D reflects vitamin D status while 1,25(OH)₂D is a tightly regulated active hormone, including PTH, FGF23 and renal control.
Read more →25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D: Physiological Meaning and Regulation: Study Summary
A concise evidence summary explaining how 25(OH)D and 1,25(OH)₂D differ in physiological meaning, regulation and their roles in vitamin D testing.
Read more →Choosing the Correct Vitamin D Biomarker: Clinical Limitations and Misinterpretation Risks: Study Summary
A concise evidence summary of vitamin D biomarker selection, common 25(OH)D and 1,25(OH)₂D testing errors, assay limitations and interpretation risks.
Read more →1,25-Dihydroxyvitamin D and the Vitamin D Receptor Gene Polymorphism Apa1 Influence Bone Mineral Density in Primary Hyperparathyroidism
Randomized, prospective studies are necessary to elucidate whether vitamin D supplementation additionally increases serum 1,25(OH)2D and possibly enhances the adverse effects on the skeleton in patients with PHPT.
Original paper ↗Read more →1,25-Dihydroxyvitamin D to PTH(1 to 84) Ratios Strongly Predict Cardiovascular Death in Heart Failure
Here, the association of 1,25(OH)2D and PTH(1 to 84) levels was evaluated for prediction of cardiovascular death in chronic HF patients.
Original paper ↗Read more →Bioconversion of vitamin D3 to bioactive calcifediol and calcitriol as high-value compounds
Biological catalysis is an important approach for the production of high-value-added compounds, especially for products with complex structures.
Original paper ↗Read more →Calcitriol, an Active Form of Vitamin D3, Mitigates Skin Barrier Dysfunction in Atopic Dermatitis NC/Nga Mice
Here, we investigated the effects of calcitriol, an active form of vitamin D3, on an NC/Nga mouse model of atopic dermatitis.
Original paper ↗Read more →Calcitriol supplementation accelerates the recovery of patients with tuberculosis who have vitamin D deficiency: a randomized, single-blind, controlled clinical trial
This study aimed to evaluate whether calcitriol supplementation enhances CD4+ T cell count and prognosis in patients with tuberculosis and low 25(OH)D levels.
Original paper ↗Read more →Circulating 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Concentrations and Postoperative Infections in Cardiac Surgical Patients: The CALCITOP-Study
In 3,340 consecutive cardiac surgical patients, we investigated the association of circulating 25-hydroxyvitamin D (25OHD; indicator of nutritional vitamin D status) and 1,25-dihydroxyvitamin D (1,25[OH]2D; active vitamin D hormone) with nosocomicial infections.
Original paper ↗Read more →Combined Treatment with Omega-3 Fatty Acid and Cholecalciferol Increases 1,25-Dihydroxyvitamin D Levels by Modulating Dysregulation of Vitamin D Metabolism in 5/6 Nephrectomy Rats
The aim of this study was to determine whether omega-3 FA and cholecalciferol have effects on vitamin D metabolism related to CYP27B1 and 24-hydroxylase (CYP24) activities in the kidney and liver of 5/6 nephrectomy (Nx) rats.
Original paper ↗Read more →Effects of Vitamin D Supplementation on IGF-1 and Calcitriol: A Randomized-Controlled Trial
We aimed to investigate effects of vitamin D supplementation on IGF-1 (primary outcome) and calcitriol (1,25(OH)2D) concentrations (secondary outcome).
Original paper ↗Read more →Low 1,25-dihydroxyvitamin D levels are associated with severe COVID-19: an observational study in hospitalized patients
This study aimed to evaluate the association of serum 25-hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D (1,25(OH)2D) levels with clinical severity and mortality among hospitalized patients with moderate and severe COVID-19.
Original paper ↗Read more →Plasma 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Levels in Breast Cancer Risk in Mali: A Case-Control Study
The aim of the current study was to determine the association between metabolites circulating in the blood, 25(OH)D and 1,25(OH)2D, and vitamin D levels with the risk of breast cancer in Malian women.
Original paper ↗Read more →Plasma 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Levels in Breast Cancer Risk in Mali: A Case-Control Study
The aim of the current study was to determine the association between metabolites circulating in the blood, 25(OH)D and 1,25(OH)2D, and vitamin D levels with the risk of breast cancer in Malian women.
Original paper ↗Read more →Pregnancy-associated alterations in circulating vitamin D metabolites: higher total 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D without increased free 25-hydroxyvitamin D
Total 25-hydroxyvitamin D [25(OH)D], free 25-hydroxyvitamin D, and total 1,25-dihydroxyvitamin D [1,25(OH)2D] concentrations were compared between pregnant and nonpregnant women and across gestation using age-adjusted regression models.
Original paper ↗Read more →Rapid Nontranscriptional Effects of Calcifediol and Calcitriol
The purpose of this paper is to provide an overview of the rapid, non-genomic effects of calcifediol and calcitriol, whose elucidation could improve the understanding of the vitamin D3 endocrine system.
Original paper ↗Read more →Vitamin D Status among Thai School Children and the Association with 1,25-Dihydroxyvitamin D and Parathyroid Hormone Levels
Only 4% (21 of 529) participants had a serum 25(OH)D level below 50 nmol/L.
Original paper ↗Read more →Vitamin D Status and Indices of Mineral Homeostasis in the Population: Differences Between 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D
This population-based study investigated cross-sectionally the associations of 25-hydroxyvitamin D (calcidiol) and 1,25-dihydroxyvitamin D (calcitriol) with indices of mineral homeostasis.
Original paper ↗Read more →Context-Dependent Association Between Serum 25-Hydroxyvitamin D and Romosozumab Bone Mineral Density Response: A Stratified Analysis by Renal Function Category and Prior Treatment History in a Real-World Japanese Cohort
This study investigated whether the renal function category and prior treatment history modified the association between baseline 25OHD and romosozumab BMD response.
Original paper ↗Read more →Original sources
Promoting improved utilization of laboratory testing through changes in an electronic medical record: experience at an academic medical center
This case study over time describes five years of experience with interventions to improve laboratory test utilization at an academic medical center.
Publication details
Promoting improved utilization of laboratory testing through changes in an electronic medical record: experience at an academic medical center. Krasowski MD et al. BMC Medical Informatics and Decision Making. 2015;15:11. PMID 25880934.
Optimizing vitamin D naming conventions in computerized order entry to support high-value care
Published in White AA, McKinney CM, Hoffman NG, Sutton PR. Journal of the American Medical Informatics Association (2017).
Publication details
Optimizing vitamin D naming conventions in computerized order entry to support high-value care. White AA, McKinney CM, Hoffman NG, Sutton PR. Journal of the American Medical Informatics Association. 2017;24:172 to 175. PMID 27107453.
The When, What & How of Measuring Vitamin D Metabolism in Clinical Medicine
We now have the ability to measure a number of different vitamin D metabolites with very accurate methods.
Publication details
The When, What & How of Measuring Vitamin D Metabolism in Clinical Medicine. Dirks NF et al. Nutrients. 2018;10:482. PMID 29652819.
Vitamin D: marker, measurand & measurement
Published in Dirks NF, Cavalier E, Heijboer AC. Endocrine Connections (2023).
Publication details
Vitamin D: marker, measurand & measurement. Dirks NF, Cavalier E, Heijboer AC. Endocrine Connections. 2023;12:e220269. PMID 36688810.
Assessment and Interpretation of Circulating 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D in the Clinical Environment
Published in Hollis BW. Endocrinology and Metabolism Clinics of North America (2010).
Publication details
Assessment and Interpretation of Circulating 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D in the Clinical Environment. Hollis BW. Endocrinology and Metabolism Clinics of North America. 2010;39:271 to 286. PMID 20511051.
Vitamin D for the Prevention of Disease
Vitamin D for the Prevention of Disease.
Publication details
Vitamin D for the Prevention of Disease. Endocrine Society clinical practice guideline. Last updated 3 June 2024.